Print
13 July 2018
GMP News
The Department of Health and Social Care (UK) is announcing the launch of a £10 million (approximately €11,3 million) research competition to fund innovations to tackle antimicrobial resistance (AMR) in humans.
AMR, which includes bacterial resistance to existing antibiotics, is on the rise and poses a significant threat to health across the world. Without a better understanding of how to tackle and prevent AMR, treatable infections could become life-threatening and the advancements made in modern medicine over recent decades are at risk of being reversed.
The competition follows the announcement of £30 (approximately €34 million) to fund research and development projects as part of the Global AMR Innovation Fund (GAMRIF) in May 2018 with CARB-X, the Foundation for Innovative New Diagnostics (FIND), the Argentinian government, and Canada’s International Development Research Centre (IDRC).
The £10 million will be made available in research grants funded through a Small Business Research Initiative (SBRI). It is being run by Innovate UK on behalf of the Department of Health and Social Care, with the aim of supporting the implementation of the UK Five Year Antimicrobial Resistance Strategy.
In 2016, a government-commissioned review highlighted the need for more research and development to reduce the global threat of AMR – prompting the government to commit to an additional investment of up to £55 million (approximately €62,15 million) over 5 years from 2016/17 towards promoting excellence in AMR research and development in the UK.
This competition, which makes available a maximum of £10 million in funding to successful bids, forms part of funding announced in October 2017 at the global ‘Call to Action’ conference by the Wellcome Trust, the UN Foundation, and the UK, Ghanaian and Thai governments, to accelerate action in this area. The registration begins on 16th of July and closes on 22nd of August 2018.
The RMI group has completed sertain projects
The RMI Group has exited from the capital of portfolio companies:
Marinus Pharmaceuticals, Inc.,
Syndax Pharmaceuticals, Inc.,
Atea Pharmaceuticals, Inc.